RecruitingNCT06401889
Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
Sponsor
Mayo Clinic
Enrollment
35 participants
Start Date
Jul 19, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.
Eligibility
Sex: FEMALEMin Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is investigating whether a skincare routine can help improve skin appearance and quality of life in postmenopausal breast cancer survivors who are taking aromatase inhibitor medications (hormone-blocking drugs that can cause skin dryness and aging as a side effect).
**You may be eligible if...**
- You are a woman aged 18 or older
- You are postmenopausal and your doctor has recommended an aromatase inhibitor for your breast cancer
- You have hormone receptor-positive breast cancer at stage 0–III
- You have not received prior chemotherapy or hormone therapy for this breast cancer
- You are willing to avoid facial procedures (fillers, lasers, Botox, etc.) during the study
**You may NOT be eligible if...**
- You have previously taken aromatase inhibitors
- You have used prescription retinoids (tretinoin), Botox, fillers, facial lasers, or microneedling in the last 6 months
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06401889
Related Trials
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT053726407 locations
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT06058377541 locations
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT0618475011 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377479 locations
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
NCT0739177421 locations